Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 4

1(14.3%)

Phase 3

1(14.3%)

7Total

N/A(5)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06079021Not ApplicableRecruiting

COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device

Role: collaborator

NCT04963920Not ApplicableSuspended

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Role: lead

NCT04391920Completed

Registry of CytoSorb Therapy in COVID-19 ICU Patients

Role: collaborator

NCT04643639Phase 3Completed

Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis

Role: collaborator

NCT05131230Withdrawn

CytoSorb® in Patients With Acute on Chronic Liver Failure

Role: lead

NCT05259514Not ApplicableTerminated

CytoSorb SAH Trial

Role: collaborator

NCT04625764Not ApplicableTerminated

Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery

Role: lead

NCT04910893Not ApplicableCompleted

Cytokine Adsorption in Severe, Refractory Septic Shock

Role: collaborator

NCT03082469Phase 4Unknown

Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal

Role: collaborator

All 9 trials loaded